Greppi, Marco
Tabellini, Giovanna
Patrizi, Ornella
Obino, Valentina
Bozzo, Matteo
Rutigliani, Mariangela
Gorlero, Franco
Di Luca, Martina
Paleari, Laura
Melaiu, Ombretta
Paudice, Michele
Loiacono, Fabrizio
Castagnola, Patrizio
Vellone, Valerio Gaetano
André, Pascale
Mavilio, Domenico
Ubezio, Gianluca
Candiani, Simona
Jandus, Camilla
Moretta, Lorenzo
De Censi, Andrea
Olive, Daniel
Sivori, Simona
Vivier, Eric
Rampinelli, Fabio
Parolini, Silvia
Pesce, Silvia
Marcenaro, Emanuela
Funding for this research was provided by:
Fondazione Umberto Veronesi (Post Doctoral Fellowship Year 2024-2025)
Fondazione AIRC per la ricerca sul cancro ETS (26037, 21147, 21147, 21147)
PRIN MIUR 2022 (2022FFALH_001)
European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC, grant agreement No. 694502, grant agreement No. 875102 - MInfla-Tilc, TILC, grant agreement No. 694502, grant agreement No. 875102 - MInfla-Tilc)
the Agence Nationale de la Recherche including the PIONEER Project (ANR-17-RHUS-0007, ANR-17-RHUS-0007)
Swiss Cancer League (KFS-5250-02-2021, KFS-5250-02-2021)
PRIN-MIUR PNRR 2022 (P2022PKFNB)
PRIN-MIUR 2022 (2022YCKH7K)
Article History
Received: 13 December 2024
Accepted: 7 August 2025
First Online: 29 August 2025
Declarations
:
: This study was carried out in accordance with the recommendations of the ethical standards of the institutional and/or national research committee. The protocol was approved by the ethics committee of the Liguria Region, Genova, Italy (n. 326/2018 and n127/2022-DB id12223 for OC patients and n. 39/2012 for healthy donors, by Spedali Civili of Brescia institutional ethical board (n. 1892/2010 for OC patients). All subjects gave written informed consent in accordance with the Declaration of Helsinki.
: All authors have approved the submitted version.
: Eric Vivier and Pascale Andrè are employees of Innate Pharma, all other authors present no Conflicts of Interest.